EzriCare Eye Drops Linked To Infections, Vision Loss and Death Reports: CDC

CDC has received at least 50 reports of severe eye infections from EzriCare Artificial Tears, including vision loss and at least one death.

  • EzriCare Artificial Tears have been linked to at least 50 reports of severe eye infections, including cases of vision loss and death
  • Contaminated eye drops may have been distributed with Pseudomonas aeruginosa bacteria
  • CDC and other health officials are actively investigating the EzriCare eye drops infections
  • Manufacturer has not issued an EzriCare Artificial Tears recall yet, but lawyers are investigating potential eye drops infection lawsuits

The U.S. Centers for Disease Control and Prevention (CDC) has issued a warning about alarming reports of severe eye infections from EzriCare Artificial Tears, indicating that the lubricating eye drops may be contaminated with drug-resistant bacteria, which may have caused permanent vision loss and at least one death.

In an EzriCare eye drops warning issued on January 20, CDC officials announced they are investigating a cluster of Pseudomonas aeruginosa bacteria infections, which have been identified among at least 50 individuals from 11 states, most of which reported using EzriCare Artificial Tears prior to infection onset.

The CDC indicates EzriCare Artificial Tears may have caused eye infections responsible for permanent vision loss, hospitalization, and one user died from a bloodstream infection following use of the eye drops.

Pseudomonas aeruginosa is a bacterium that can cause mild to severe infections in humans, resulting in fever, chills, body aches, light-headedness, rapid pulse, heavy breathing, nausea and vomiting, diarrhea and decreased urination. The infection can be fatal due to many of its strains commonly being resistant to antibiotics, which limits treatment options, especially among those already suffering from weakened immune systems or pre-existing lung conditions.

Learn More About

Eye Drops Recall Lawsuits

Lawyers are investigating EzriCare Artificial Tears eye infection lawsuits for individuals who experienced problems following use of recalled eye drops.


Warning About EzriCare Eye Drops Vision Loss Risk

EzriCare Artificial Tears are advertised as a “preservative-free” and “proprietary natural tears formula,” which is supposed to mimic natural tears to provide relief for those experiencing dry, red, scratchy, itchy, or gritty eyes.

The EzriCare eye drops are offered as an over-the-counter (OTC) product through a variety of stores and online retailers, such as Walmart and Amazon.com. The artificial tears are formulated, designed, and imported by Aru Pharma Inc. in the United States, and are manufactured by Global Pharma Healthcare PVT LTD in India.

According to data collected by the CDC and local health departments between May 17, 2022 and January 19, 2023, at least 50 reports of individuals developing antibiotic-resistant bacterial infections from EzriCare eye drops have been identified in California, Colorado, Connecticut, Florida, New Jersey, New Mexico, New York, Nevada, Texas, Utah and Washington.

Officials reported that of the users who developed an ocular infection, at least three users experienced blindness in one eye, while other users reportedly developed respiratory infections and urinary tract infections. To date, the agency is aware of one death caused by Pseudomonas aeruginosa entering their bloodstream after using the eye drops.

Preliminary findings of the CDC’s epidemiological investigation has identified that most patients reported using EzriCare Artificial Tears before developing infections. Officials confirmed that laboratory analyses of open EzriCare bottles collected from patients were contaminated with Pseudomonas aeruginosa.

The CDC has also collected fifty-six isolates from infected patients, which the agency stated will be cross-referenced against samples collected from the opened and unopened bottles of EzriCare Artificial Tears to determine whether they contain the same strain of Pseudomonas aeruginosa.

Out of an abundance of caution, officials are instructing customers, health care providers and patients immediately discontinue using the EzriCare drops due to the risk of bacterial infection. However, lawyers indicate that if users experienced any eye problems from the EzriCare artificial tears, the product should be safely stored for future testing as part of any eye drop infection lawsuit that may be pursued.

EzriCare Artificial Tears Recall May Be Imminent

As the CDC continues to investigate the outbreak of the infection potentially linked to the products, the manufacturer has yet to announce an EzriCare Artificial Tears recall.

Four days after the CDC’s warning, the company released a statement on its website on January 24, acknowledging that the Pseudomonas aeruginosa infections may be linked to its eye drops products. However, the statement indicates the company has yet to receive any consumer complaints or adverse reports, and has not been asked by deferral regulators to take any action.

The company’s statement implies that no EzriCare Artificial Tears recall was being initiated at that time. However, the manufacturer has recommended customers stop using the EzriCare Artificial Tears at this time, and it is expected that retailers or federal regulators may soon force an EzriCare eye drops recall.

Given the large number of eye infections reported before the first CDC warnings were even issued, it is expected that the extent of problems may be much more widespread, and it is likely that EzriCare eye drops lawsuits will be filed in the coming weeks and months if it is confirmed that the artificial tears were distributed with drug-resistant bacteria.

Contact A Lawyer


If you or a loved one required medical treatment for an eye infection cauzed by EzriCare Artificial Tears, financial compensation may be available through an eye drops recall settlement. Lawyers provide free consultations and claim evaluations to help determine if you or a loved one may qualify.

Image Credit: |


Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Leadership Development Committee for Suboxone Dental Injury Lawyers Established in Federal MDL
Leadership Development Committee for Suboxone Dental Injury Lawyers Established in Federal MDL (Posted yesterday)

The U.S. District Judge presiding over all Suboxone lawsuits has created a mentorship program to use the litigation to provide some attorneys an opportunity to gain experience in handling complex federal multidistrict litigations.

Gilead Settlement Resolves 2,625 HIV Drug Lawsuits Pending in Federal Courts for $40M
Gilead Settlement Resolves 2,625 HIV Drug Lawsuits Pending in Federal Courts for $40M (Posted 3 days ago)

Gilead says it will pay $40 million to resolve HIV drug lawsuits over Truvada, Atripla, Viread, Stribild and Complera pending in the federal court system, involving claims that the the company sat on safer formulations of the drugs for years to increase profits.